Table 6.
Independent association of Anti-N-Ab level on adjustment of confounding variables.
| Variables | Male |
Female |
Total |
|||
|---|---|---|---|---|---|---|
| RC (95 % CI) | p value | RC (95 % CI) | p value | RC (95 % CI) | p value | |
| Age, year | 0.13 (−0.03–0.12) | 0.251 | −0.08 (−0.09–0.04) | 0.467 | 0.05(-0.03–0.07) | 0.537 |
| BMI | −0.04 (−0.19–0.12) | 0.681 | −0.07 (−0.17–0.07) | 0.415 | −0.05(-0.13–0.05) | 0.415 |
| WHR | −0.22(-19.01–−0.74) | 0.034 | 0.07 (−4.73–11.16) | 0.425 | −0.04(-7.35–3.86) | 0.539 |
| Comorbidity | 0.05 (−1.45–2.35) | 0.639 | −0.12 (−2.35–0.51) | 0.206 | −0.03 (−1.31–0.93) | 0.732 |
| Covid Symptom Positivity any time | −0.19 (−3.54–0.14) | 0.070 | 1.00(-0.57–2.01) | 0.270 | −0.04 (−1.34–0.70) | 0.541 |
| Covid Symptom Positivity during last 3 months | −0.11(-4.15–1.30) | 0.302 | 0.06 (−1.01–2.12) | 0.487 | −0.01 (−1.39–1.18) | 0.870 |
| Covid rtPCR test positivity, anytime | 0.07(-1.14–2.33) | 0.499 | −0.06 (−1.90–0.99) | 0.540 | −0.01(-1.18–1.02) | 0.886 |
| Covid rtPCR test positivity during last 3 months | −0.01 (−3.84–3.46) | 0.918 | −0.16 (−5.23–0.18) | 0.067 | −0.10(-3.75–0.50) | 0.133 |
| Days after Dose1 vaccine | −0.14 (−0.02–0.01) | 0.342 | −0.02 (−0.01–0.01) | 0.837 | −0.03 (−0.01–0.01) | 0.751 |
| Days after Dose2 vaccine | 0.08 (−0.01–0.02) | 0.606 | 0.08 (−0.01–0.01) | 0.515 | 0.06(-0.01–0.01) | 0.483 |
| Days after Dose 3 vaccine | 0.19 (−0.02–0.08) | 0.272 | −0.03 (−0.05–0.04) | 0.832 | 0.10(-0.02–0.05) | 0.355 |
| Vaccine Dose 3 Received | 0.17 (−1.36–4.07) | 0 0.325 | 0.11 (−1.47–3.10) | 0.481 | 0.164(-0.41–3.01) | 0.137 |
| Constant | −1.84–29.90 | 0.082 | −4.67–16.56 | 0.270 | −1.14–15.06 | 0.092 |
Data were analyzed by multivariable linear regression analysis. Anti-N-Ab level was considered as the dependent variable; RC=Regression Coefficients, 95 % CI (95 % Confidence Interval); p < 0.05 was considered as significant.